• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GB Capital Ltd. Co-Advises on the Acquisition of SVM Machining, Inc.

    2/12/26 4:30:00 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email

    VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- GB Capital Ltd. ("GB Capital"), a strategic finance, advisory and management firm, today announced that it served as co-advisor to PMGC Holdings  Inc. (NASDAQ:ELAB) ("PMGC") in connection with PMGC's acquisition of SVM Machining, Inc. ("SVM"), a Northern California–based ISO 9001:2015 certified CNC precision machining company.

    As disclosed by PMGC in its public announcement of the transaction (available here), the acquisition supports PMGC's strategy of building a scaled, multi-site U.S. precision manufacturing platform through the acquisition and integration of profitable, high-quality operating businesses.

    Transaction Highlights

    • Acquirer: PMGC Holdings Inc.
    • Target: SVM Machining, Inc.
    • Transaction Type: Acquisition of 100% of the issued and outstanding shares of SVM on a cash-free, debt-free basis
    • Closing Date: February 2, 2026



    Founded in 1997, SVM Machining (also known as Silicon Valley Manufacturing) provides high-precision CNC machining services to customers across medical technology, aerospace, semiconductor, biotech & pharmaceutical, and transportation end markets.

    GB Capital advised PMGC across all major aspects of the transaction and led the financial due diligence process, including quality of earnings analysis, working capital assessment, audit coordination, and preparation of historical financial statements and supporting schedules to support a U.S. GAAP compliant audit and post-acquisition reporting requirements. GB Capital also supported transaction structuring, valuation analysis, negotiation support, and coordination with legal, tax, and audit stakeholders.

    In addition to transaction advisory services, GB Capital is supporting post-closing transition and integration services, including ongoing financial back-office support and the implementation of GB Capital's proprietary C.O.R.E. Financial Framework™ (Compliant, Organized Reporting Engine) to standardize accounting, reporting, and internal controls to support ongoing U.S. GAAP compliance, audit readiness, and repeatable financial reporting across PMGC's manufacturing platform.

    About GB Capital Ltd.

    GB Capital Ltd. is a strategic finance, advisory and management firm focused on working with growth-stage and publicly listed companies. The firm provides end-to-end support across M&A advisory, capital markets strategy, financial reporting and audit readiness, strategic finance leadership, and public-company compliance. GB Capital partners with management teams early to build scalable financial infrastructure and execute complex transactions with institutional-grade rigor.

    For more information, visit www.gbcapital.ca.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements.

    Disclaimer

    This press release is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities.

    Contact: [email protected]



    Primary Logo

    Get the next $ELAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    SEC Filings

    View All

    PMGC Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    3/10/26 4:01:57 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    3/3/26 7:51:43 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    2/19/26 9:29:49 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Parry Jeffrey claimed ownership of 3 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    2/10/26 9:43:04 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Daley Juliana claimed ownership of 1 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    2/9/26 8:31:19 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Kovalyov George claimed no ownership of stock in the company (SEC Form 3)

    3 - PMGC Holdings Inc. (0001840563) (Issuer)

    1/29/26 8:08:05 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

    NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

    2/3/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC

    Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2

    7/18/25 12:53:12 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

    Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

    7/10/25 8:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

    NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. ("NorthStrive Biosciences"). The study is designed to evaluate EL-32's potential to preserve lean muscle mass while promoting fat loss, both as a standalone therapy and in combination with GLP-1 weight loss treatments. This announcement follows the Company's January 30, 2025 press release titled "NorthStrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement for Preclinical Mouse St

    3/10/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

    NEWPORT BEACH, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-6 reverse stock split (the "Split") of its issued and outstanding and authorized common stock, par value $0.0001 per share ("Common Stock"), effective at 12:00 am, Eastern time, on March 10, 2026. Key Details of the Reverse Stock Split: Conversion Ratio: Every 6 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 6 shares of authorized Common Stock will be consolidated into one share of Common Stock, each with no further action required from shareholders.Fractional Shares:

    3/4/26 5:30:00 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum

    DENVER, Feb. 19, 2026 (GLOBE NEWSWIRE) -- U.S. equity markets are pointing modestly lower this Thursday morning. The focus remains on earnings season kickoff and any fresh Fed commentary, but today's headlines are dominated by transformative deals and production milestones that are lifting small- and mid-cap names. Key Movers & Catalysts Driving the Tape Interactive Strength (NASDAQ:TRNR) is the standout gainer pre-market, surging more than 40% after announcing a definitive agreement to acquire Ergatta, the game-based connected fitness pioneer. The deal boosts TRNR's 2026 pro forma revenue guidance by 50%, to more than $30 million, with Ergatta alone expected to deliver > $10 million in

    2/19/26 11:00:26 AM ET
    $ELAB
    $TOVX
    $TRNR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Consumer Electronics/Appliances
    Technology

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care